Simulation-guided phase 3 trial design to evaluate vaccine effectiveness to prevent Ebola virus disease infection: Statistical considerations, design rationale, and challenges.

Vandebosch, A; Mogg, R; Goeyvaerts, N; Truyers, C; Greenwood, B; Watson-Jones, D; Herrera-Taracena, G; Parys, W; Vangeneugden, T; (2016) Simulation-guided phase 3 trial design to evaluate vaccine effectiveness to prevent Ebola virus disease infection: Statistical considerations, design rationale, and challenges. Clinical trials (London, England), 13 (1). pp. 57-65. ISSN 1740-7745 DOI: https://doi.org/10.1177/1740774515621059

Permanent Identifier

Use this Digital Object Identifier when citing or linking to this resource.

https://doi.org/10.1177/1740774515621059

Abstract

Share

Download

Filename: JCT_Phase3_revision2_final_corrected_1.docx

Licence: Creative Commons: Attribution-Noncommercial-No Derivative Works 3.0

Download
[img]

Downloads

View details

Metrics & Citations


Google Scholar